A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

NCT00000846 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: HIV-1 Peptide Vaccine, Microparticulate Monovalent
BIOLOGICAL: HIV-1 Peptide Immunogen, Multivalent

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)